SynCore Biotechnology Co.,Ltd (TPEX:4192)
19.95
+0.10 (0.50%)
Apr 27, 2026, 2:31 PM CST
TPEX:4192 Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | -45.76 | -54.28 | -38.17 | -188.67 | -458.6 | Upgrade
|
| Depreciation & Amortization | 17.39 | 17.85 | 19.09 | 38.86 | 17 | Upgrade
|
| Other Amortization | 0.19 | 0.33 | 0.57 | 1.21 | 35.43 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.12 | -0.3 | - | 0.13 | - | Upgrade
|
| Other Operating Activities | -0 | 0.01 | -60.41 | -0.06 | -0.06 | Upgrade
|
| Change in Accounts Receivable | -3.32 | 0.17 | -0.77 | 0.01 | -0.57 | Upgrade
|
| Change in Inventory | 0.38 | -6.93 | 14.36 | -0.3 | 0.67 | Upgrade
|
| Change in Accounts Payable | -8.26 | 9.32 | -0.32 | 0.32 | -11.4 | Upgrade
|
| Change in Unearned Revenue | 0.83 | - | - | - | - | Upgrade
|
| Change in Other Net Operating Assets | 0.33 | -15.4 | -16.73 | -61.11 | 187.67 | Upgrade
|
| Operating Cash Flow | -38.33 | -49.24 | -82.37 | -209.61 | -229.86 | Upgrade
|
| Capital Expenditures | -0.23 | -0.21 | -0.42 | -0.14 | -0.29 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | - | 0.01 | - | Upgrade
|
| Sale (Purchase) of Intangibles | -0.17 | -0.25 | -0.35 | -0.9 | -1.35 | Upgrade
|
| Investment in Securities | 0.54 | - | - | - | - | Upgrade
|
| Other Investing Activities | -0.39 | - | -0.02 | - | - | Upgrade
|
| Investing Cash Flow | -0.25 | -0.46 | -0.78 | -1.03 | -1.64 | Upgrade
|
| Long-Term Debt Issued | - | - | - | 30 | - | Upgrade
|
| Total Debt Issued | - | - | - | 30 | - | Upgrade
|
| Short-Term Debt Repaid | - | - | -60 | -60 | -60 | Upgrade
|
| Long-Term Debt Repaid | -9.63 | -9.51 | -10.61 | -43.21 | -43.19 | Upgrade
|
| Total Debt Repaid | -9.63 | -9.51 | -70.61 | -103.21 | -103.19 | Upgrade
|
| Net Debt Issued (Repaid) | -9.63 | -9.51 | -70.61 | -73.21 | -103.19 | Upgrade
|
| Issuance of Common Stock | - | - | 149.28 | - | 348.5 | Upgrade
|
| Financing Cash Flow | -9.63 | -9.51 | 78.68 | -73.21 | 245.31 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.06 | 0 | 0.03 | 0.03 | -0.08 | Upgrade
|
| Net Cash Flow | -48.15 | -59.21 | -4.45 | -283.83 | 13.74 | Upgrade
|
| Free Cash Flow | -38.57 | -49.45 | -82.79 | -209.75 | -230.15 | Upgrade
|
| Free Cash Flow Margin | -142.61% | -211.89% | -409.92% | -1322.74% | -3316.73% | Upgrade
|
| Free Cash Flow Per Share | -1.10 | -1.41 | -2.58 | -6.82 | -7.58 | Upgrade
|
| Cash Interest Paid | 0.17 | 0.3 | 0.81 | 2.31 | 2.1 | Upgrade
|
| Levered Free Cash Flow | -22.47 | -31.41 | -73.89 | -143.2 | -60.81 | Upgrade
|
| Unlevered Free Cash Flow | -22.37 | -31.22 | -73.4 | -141.78 | -59.54 | Upgrade
|
| Change in Working Capital | -10.04 | -12.85 | -3.45 | -61.08 | 176.37 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.